127 related articles for article (PubMed ID: 10542949)
1. Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis.
Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
Int J Gynecol Pathol; 1999 Oct; 18(4):387-91. PubMed ID: 10542949
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
[TBL] [Abstract][Full Text] [Related]
4. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility.
Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
Carcinogenesis; 1997 Dec; 18(12):2307-11. PubMed ID: 9450474
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation.
Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
Am J Clin Pathol; 1999 Mar; 111(3):336-42. PubMed ID: 10078108
[TBL] [Abstract][Full Text] [Related]
6. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
7. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
8. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.
Fournier DB; Chisamore M; Lurain JR; Rademaker AW; Jordan VC; Tonetti DA
Gynecol Oncol; 2001 Jun; 81(3):366-72. PubMed ID: 11371124
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
12. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen.
Elkas J; Armstrong A; Pohl J; Cuttitta F; Martínez A; Gray K
Obstet Gynecol; 2000 May; 95(5):697-703. PubMed ID: 10775732
[TBL] [Abstract][Full Text] [Related]
13. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
14. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and the endometrium.
Barakat RR
Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689
[No Abstract] [Full Text] [Related]
16. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
17. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
Magriples U; Naftolin F; Schwartz PE; Carcangiu ML
J Clin Oncol; 1993 Mar; 11(3):485-90. PubMed ID: 8383191
[TBL] [Abstract][Full Text] [Related]
18. Synchronous metastasis from lobular carcinoma and primary carcinoma of the endometrium in a patient after tamoxifen therapy.
Vicioso L; Ortega MV; Cívico V; López-Beltrán A
Int J Gynecol Pathol; 2013 Jan; 32(1):66-70. PubMed ID: 23202785
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
20. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.
Bachleitner-Hofmann T; Pichler-Gebhard B; Rudas M; Gnant M; Taucher S; Kandioler D; Janschek E; Dubsky P; Roka S; Sporn E; Jakesz R
Clin Cancer Res; 2002 Nov; 8(11):3427-32. PubMed ID: 12429630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
